Denali Therapeutics
- Market cap
- 3.06B
- P/E (TTM)i
- -6.75
- P/Bi
- 3.67
- EPSi
- -2.97
- Div yieldi
- 0.00%
- 52W posi
- 40%
Anonymous reader poll. Unscientific, not investment advice.
Denali Therapeutics ended the session at 19.16, down 0.62%. That leaves the company valued at approximately 3.06B, the #2454 most valuable US-listed company we track. The 13 analysts covering the stock are, on balance, at Buy, targeting an average of 35.09 (+83%). Over the past year the stock has ranged from 13.75 to 27.30; it now sits 40% up that band.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 3 weeks.
- Its last 4 Sell calls were followed by a 24% average decline over the next quarter.
- Recent price momentum is +0.7% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 10.7% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 19.28
- Open
- 18.95
- Day range
- 18.89 - 19.43
- Avg price
- 19.20
- Volume
- 1.31M
- Turnover
- 25.23M
- Turnover ratei
- 0.85%
- Volume ratioi
- 0.59
- Amplitudei
- 2.80%
- 52-week rangei
- 13.75 - 27.30
Valuation
- P/Ei
- -6.45
- P/E (TTM)i
- -6.75
- P/Bi
- 3.67
- EPSi
- -2.97
- Book value / shi
- 5.23
- Net profit
- -474.75M
- Net assets
- 835.20M
Share structure
- Market cap
- 3.06B
- Float capi
- 2.97B
- Shares out
- 159.85M
- Float sharesi
- 155.09M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2017-12-08
29.8% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-12.12M net over the window
Short interest
- Shares short
- 17.14M
- % of floati
- 10.72%
- Days to coveri
- 11.97
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Denali Therapeutics (DNLI)?
Denali Therapeutics last traded at 19.16. The quote on this page refreshes every few seconds while US markets are open.
What is Denali Therapeutics's market cap?
About 3.06B.
What is the P/E ratio of Denali Therapeutics?
The trailing twelve-month P/E is -6.75. The Valuation tab shows it against the stock's own five-year range.
Does Denali Therapeutics pay a dividend?
Denali Therapeutics does not currently pay a regular dividend.
Is Denali Therapeutics a buy according to analysts?
The consensus of 13 analysts is a Buy rating, with an average 12-month price target of 35.09, which implies 83.1% upside from the current price. This is not investment advice.
What is Denali Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Denali Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-10-08 07:00:03 · For reference only, not investment advice and not tailored to your situation.